Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NMT2 | O60551 | 1/20 | 0.48 |
| ▸ | NMT1 | P30419 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1178069 | 0.92 | KMT2A (0.58) | MEN1KMT2AMAPK10MAPTGAA | |
| SCHEMBL1467189 | 0.89 | MAPK1 (0.63) | MEN1KMT2AMAPK10MAPTGAA | |
| SCHEMBL27720570 | 0.88 | MAPT (0.54) | MEN1KMT2AMAPK10MAPTGAA | |
| SCHEMBL10991178 | 0.88 | MEN1 (0.64) | MEN1KMT2AMAPK10MAPTGAA | |
| SCHEMBL27252854 | 0.88 | MEN1 (0.64) | MEN1KMT2AMAPK10MAPTGAA | |
| SCHEMBL30900718 | 0.88 | MEN1 (0.64) | MEN1KMT2AMAPK10MAPTGAA | |
| SCHEMBL441687 | 0.87 | KMT2A (0.62) | MEN1KMT2AMAPK10MAPTGAA | |
| SCHEMBL3881231 | 0.87 | MEN1 (0.53) | MEN1KMT2AMAPK10MAPTGAA | |
| SCHEMBL401916 | 0.87 | MAPK1 (0.65) | MEN1KMT2AMAPK10MAPTGAA | |
| SCHEMBL30900720 | 0.87 | NMT2 (0.60) | MEN1KMT2AMAPK10MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514791-A1 | SUBSTITUTED 6- (PYRIMIDIN-4-YL) QUINOLINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2025-03-05 | — | — | EP | disclosed |
| CN-119095840-A | Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors | 百济神州有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240300937-A1 | Substituted 6-(Pyrimidin-4-yl)Quinoline Compounds as Cyclin Dependent Kinase Inhibitors | BEIGENE, LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| CN-117771374-A | Application of NUDT1 in preparing medicine for treating MYC high expression or MYC amplified tumor | 武汉大学 | 2024-03-29 | — | — | CN | disclosed |
| US-11827636-B2 | Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827636-B2 | Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2023208173-A1 | SUBSTITUTED 6- (PYRIMIDIN-4-YL) QUINOLINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BEIGENE , LTD. (KY) | 2023-11-02 | — | — | WO | disclosed |
| CN-109311869-B | Degradation of CDK8 by conjugation of cyclin-dependent kinase 8 (CDK 8) inhibitors to E3 ligase ligands and methods of use | 达纳－法伯癌症研究所公司 | 2022-12-23 | — | — | CN | disclosed |
| US-11427582-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | UWM RESEARCH FOUNDATION, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3445764-B1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 8 (CDK8) BY CONJUGATION OF CDK8 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-2350053-A2 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | Whitehead Institute For Biomedical Research (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010044885-A2 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010044885-A2 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2010-04-22 | — | — | WO | disclosed |
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| US-4788188-A | ANTICONVULSANTS, SEDATIVES, ANXIOLYTIC AGENTS | SANOFI (S.A.) (FR) | 1988-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827636-B2 | Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use | CDK8, CDK18, CDKL3 | MEN1 2825/4885KMT2A 417/4885MAPK10 831/4885 |
| US-11427582-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | GABRA6, HTR6, GABRD | MEN1 3061/4885KMT2A 3519/4885MAPK10 4530/4885 |
| US-20240300937-A1 | Substituted 6-(Pyrimidin-4-yl)Quinoline Compounds as Cyclin Dependent Kinase Inhibitors | CDK4, CDK6, CDK2 | MEN1 3095/4885KMT2A 601/4885MAPK10 426/4885 |
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | MEN1 2733/4885KMT2A 2305/4885MAPK10 1742/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | MEN1 2733/4885KMT2A 2305/4885MAPK10 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.